Park Ha Biological Technology Co Ltd

Análisis de la acción Park Ha Biological Technology Co Ltd (BYAH)

$2.200

-0.175 (-7.95%)Al cierre

Loading chart…
Máximo
2.398
Apertura
2.390
Precio medio ponderado por volumen
2.26
Volumen
15.30K
Capitalización
—
Mínimo
2.190
Importe
34.63K
EV/EBITDA, TTM
0.00

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market.

ir.parkha.cn

Análisis de IA of Park Ha Biological Technology Co Ltd (BYAH)

Vender

Given the current price of $2.20 and a year-to-date change of -96.77%, BYAH is not a good buy right now. The RSI is at 29.607, indicating that the stock is oversold, but the negative performance trends and high volatility suggest significant risks. The forward P/E is 0, indicating uncertainty about future earnings, and the stock has dropped 98.57% over the past year, which raises serious concerns about its viability.

Métricas de valoración

El PER previsto actual de Park Ha Biological Technology Co Ltd (BYAH) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Cronología de eventos

2026-08-05 (ET)

20:00:00

Park Ha Biological Technology Co Ltd Trading Halted, News Pending

2026-06-29 (ET)

10:30:00

Park Ha Biological Partners with Amazon for North American Market Entry

2026-06-23 (ET)

09:30:00

Park Ha Biological Establishes Strategic Partnership with Cloud Factory Technology

2026-06-12 (ET)

15:00:00

Park Ha Biological Technology Raises $2M in Direct Offering

09:00:00

Park Ha Biological Partners with Star Plus Action

Noticias

Preguntas frecuentes sobre BYAH, respondidas por Alphio AI

Park Ha Biological Technology Co Ltd is an investment holding company primarily engaged in developing private skincare label, direct skincare products sales and franchise alliances promotions. The Company mainly operates its business through two segments. The Products Sales segment is engaged in providing skincare and cosmetic products under the brand name Park Ha as well as offering complimentary after-sales beauty services in physical stores. The Franchise Service segment is engaged in entering franchise agreements with its franchisees, pursuant to which the franchisees are granted permission to open and operate a store under the brand name Park Ha or Geni. The Company's products include Little Blue Injection Serum, Parkha Amino Acid Cleansing Foam and other products. The Company mainly conducts its business in domestic market. It operates in the Consumer Non-Cyclicals sector.

Given the current price of $2.20 and a year-to-date change of -96.77%, BYAH is not a good buy right now. The RSI is at 29.607, indicating that the stock is oversold, but the negative performance trends and high volatility suggest significant risks. The forward P/E is 0, indicating uncertainty about future earnings, and the stock has dropped 98.57% over the past year, which raises serious concerns about its viability.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar